GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » EV-to-EBIT

Genovate Biotechnology Co (ROCO:4130) EV-to-EBIT : 57.80 (As of Jun. 10, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genovate Biotechnology Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Genovate Biotechnology Co's Enterprise Value is NT$2,143.9 Mil. Genovate Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$37.1 Mil. Therefore, Genovate Biotechnology Co's EV-to-EBIT for today is 57.80.

The historical rank and industry rank for Genovate Biotechnology Co's EV-to-EBIT or its related term are showing as below:

ROCO:4130' s EV-to-EBIT Range Over the Past 10 Years
Min: -510.93   Med: 62.49   Max: 615.51
Current: 57.8

During the past 13 years, the highest EV-to-EBIT of Genovate Biotechnology Co was 615.51. The lowest was -510.93. And the median was 62.49.

ROCO:4130's EV-to-EBIT is ranked worse than
88% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs ROCO:4130: 57.80

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Genovate Biotechnology Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$2,215.0 Mil. Genovate Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$37.1 Mil. Genovate Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.67%.


Genovate Biotechnology Co EV-to-EBIT Historical Data

The historical data trend for Genovate Biotechnology Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovate Biotechnology Co EV-to-EBIT Chart

Genovate Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.29 66.96 598.65 -350.87 76.25

Genovate Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.47 114.91 70.92 76.25 59.71

Competitive Comparison of Genovate Biotechnology Co's EV-to-EBIT

For the Biotechnology subindustry, Genovate Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovate Biotechnology Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genovate Biotechnology Co's EV-to-EBIT falls into.



Genovate Biotechnology Co EV-to-EBIT Calculation

Genovate Biotechnology Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2143.872/37.094
=57.80

Genovate Biotechnology Co's current Enterprise Value is NT$2,143.9 Mil.
Genovate Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$37.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genovate Biotechnology Co  (ROCO:4130) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Genovate Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=37.094/2214.9714
=1.67 %

Genovate Biotechnology Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$2,215.0 Mil.
Genovate Biotechnology Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$37.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genovate Biotechnology Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Genovate Biotechnology Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Genovate Biotechnology Co (ROCO:4130) Business Description

Traded in Other Exchanges
N/A
Address
No.1, First Industrial Road, Hsin-Chu Industrial Zone, Guangdong Province, Hsin-Chu, TWN
Genovate Biotechnology Co Ltd develops, manufactures and markets pharmaceutical preparations, drug substances and intermediates. Its product line includes nervous system drugs, digestive system drugs and cardiovascular system drugs, among others. It also provides clinical trial services for various drugs.

Genovate Biotechnology Co (ROCO:4130) Headlines

No Headlines